Targeted Glioma Therapy—Clinical Trials and Future Directions
Glioblastoma multiforme (GBM) is the most common type of glioma, with a median survival of 14.6 months post-diagnosis. Understanding the molecular profile of such tumors allowed the development of specific targeted therapies toward GBM, with a major role attributed to tyrosine kinase receptor inhibi...
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
MDPI AG
2024-01-01
|
| coleção: | Pharmaceutics |
| Assuntos: | |
| Acesso em linha: | https://www.mdpi.com/1999-4923/16/1/100 |